You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive breast cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Eribulin mesylate injection、Pertuzumab、Trastuzumab
  • Guanzhou, Guangdong, China
    LI YuDong
Jul 13, 2023

HER2-positive Breast Cancer Trial in Shenyang (SHR-A1811, Pyrotinib)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Dec 1, 2022

HER2-positive Breast Cancer Trial in Ireland (trastuzumab deruxtecan (T-DXd) (IV))

Not yet recruiting
  • HER2-positive Breast Cancer
  • trastuzumab deruxtecan (T-DXd) (IV)
  • Galway, Connaught, Ireland
  • +4 more
Jan 24, 2023

Early-stage HER2-positive Breast Cancer, Treated With Neratinib

Recruiting
  • Breast Cancer
  • +2 more
    • Bouge, Belgium
      Clinique Saint-Luc Bouge
    Oct 25, 2022

    HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)

    Recruiting
    • HER2-positive Breast Cancer
    • Dendritic Cell (DC1) Vaccine
    • +3 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    Breast Cancer, Brain Metastases, HER2-positive Breast Cancer Trial in Shanghai (Pyrotinib Plus Capecitabine combined with brain

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Pyrotinib Plus Capecitabine combined with brain radiotherapy
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Jan 14, 2023

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)

    Recruiting
    • Breast Cancer
    • +5 more
    • 89Zr-DFO*-trastuzumab PET scan
    • Amsterdam, Noord-Holland, Netherlands
      AmsterdamUMC
    Jul 12, 2023

    T-Dxd in Treatment of HER2-positive BCBM After Prior Pyrotinib

    Recruiting
    • Breast Cancer
    • Beijing, Beijing, China
    • +1 more
    Nov 13, 2023

    Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)

    Not yet recruiting
    • Brain Metastases
    • HER2-positive Breast Cancer
    • Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
    • (no location specified)
    Jan 10, 2023

    HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
    • (no location specified)
    Jul 20, 2023

    HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

    Recruiting
    • HER2-positive Breast Cancer
    • Acquisition of blood samples and tumour tissue samples (biopsies)
    • Brighton, United Kingdom
    • +1 more
    Nov 9, 2022

    T-Dxd in Chinese Metastatic HER2-positive Breast Cancer Patients

    Active, not recruiting
    • Breast Cancer
    • Trastuzumab Deruxtecan
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 25, 2022

    Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)

    Recruiting
    • Triple Negative Breast Cancer
    • HER2-positive Breast Cancer
    • proton plus carbon ion radiotherapy
    • Shanghai, China
      Shanghai Proton and Heavy Ion center
    Jan 11, 2023

    HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Jan 30, 2023

    Breast Cancer Trial in Moscow, Omsk, Saint Petersburg (BCD-178, Perjeta)

    Recruiting
    • Breast Cancer
    • Moscow, Russian Federation
    • +2 more
    Apr 5, 2023

    Breast Cancer Trial in Sweden (Trastuzumab deruxtecan, Docetaxel, Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • Trastuzumab deruxtecan
    • +9 more
    • Malmö, Sweden
    • +6 more
    Jun 8, 2023

    Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic

    Completed
    • Breast Cancer
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Apr 20, 2023

      HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)

      Not yet recruiting
      • HER2-positive Breast Cancer
      • LMD
      • Tucatinib 150 MG
      • +3 more
      • (no location specified)
      Aug 24, 2023

      Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin +

      Recruiting
      • Breast Cancer
      • HER2-positive Breast Cancer
      • Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
      • (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
      • Zhengzhou, Henan, China
        Henan cancer hospital
      Jul 24, 2022

      Breast Cancer Trial in Beijing (99mTc-MIRC213)

      Recruiting
      • Breast Cancer
      • Beijing, China
        Peking Union Medical College Hospital, Chinese Academy of Medica
      Nov 18, 2022

      Metastatic HER2-Positive Breast Cancer Trial in United States (Gemcitabine, Trastuzumab, Pertuzumab)

      Active, not recruiting
      • Metastatic HER2-Positive Breast Cancer
      • Hartford, Connecticut
      • +4 more
      Dec 1, 2022

      Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)

      Recruiting
      • Locally Advanced Breast Cancer
      • Shanghai, Shanghai, China
        Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
      Aug 11, 2022

      Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)

      Active, not recruiting
      • Advanced/ Metastatic Her-2 Positive Breast Cancer
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Nov 15, 2022

      Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

      Not yet recruiting
      • Breast Cancer
      • +2 more
      • Cessation of anti-HER2 treatment
      • Boston, Massachusetts
      • +1 more
      Feb 9, 2023